This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Interesting Results in a Trial of Prednisone

Michael H. Brooke, MD; Gerald M. Fenichel, MD; Robert C. Griggs, MD; Jerry R. Mendell, MD; Richard T. Moxley III, MD; J. Philip Miller; Kenneth K. Kaiser; Julaine M. Florence, MHS; Shree Pandya, MS; Linda Signore, BSN; Wendy King; Jenny Robison; Richard A. Head, MD; Michael A. Province, PhD; Warren Seyfried, PhD; Stephen Mandel

Arch Neurol. 1987;44(8):812-817.

Abstract
• We investigated the effect of highdose prednisone therapy in 33 boys with Duchenne muscular dystrophy. The drug was given daily in doses of 1.5 mg/kg of body weight (to a maximum of 80 mg) for six months. Muscle strength, joint contractures, timed functional tests, functional ability, and pulmonary function were measured at the beginning and end of the treatment period. The trial was designed using natural history controls, and the power of the study was 0.80 to detect a slowing of 50% in the rate of progression. During the period of the trial, muscle strength, functional grades, timed functional tests, and pulmonary function improved. Contractures followed the expected natural history of the illness.

Author Affiliations
From the Washington University School of Medicine, St Louis (Drs Brooke, Head, Province, and Seyfried, Messrs Miller, Mandel and Kaiser, and Ms Florence); Vanderbilt University, Nashville, Tenn (Dr Fenichel and Ms Robison); University of Rochester (NY) (Drs Griggs, Moxley, and Ms Pandya); and Ohio State University, Columbus (Dr Mendell, and Mss Signore and King).

Footnotes
Accepted for publication April 15, 1987.

Reprint requests to Department of Neurology, Washington University Medical School, 660 S Euclid, Box 8111, St Louis, MO 63110 (Dr Brooke).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy
Bonifati et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:1177-1179.
ABSTRACT | FULL TEXT  

Steroid Treatment for Cardiac Function in Duchenne Muscular Dystrophy
Danford
AAP Grand Rounds 2006;15:58-59.
FULL TEXT  

The Muscular Dystrophies: From Genes to Therapies
Lovering et al.
ptjournal 2005;85:1372-1388.
ABSTRACT | FULL TEXT  

Challenges and opportunities in clinical trials for spinal muscular atrophy
Hirtz et al.
Neurology 2005;65:1352-1357.
ABSTRACT | FULL TEXT  

Practice Parameter: Corticosteroid treatment of Duchenne dystrophy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society
Moxley et al.
Neurology 2005;64:13-20.
ABSTRACT | FULL TEXT  

Corticosteroids in Duchenne Muscular Dystrophy: A Reappraisal
Wong and Christopher
J Child Neurol 2002;17:183-190.
ABSTRACT  

A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy
Fenichel et al.
Neurology 2001;56:1075-1079.
ABSTRACT | FULL TEXT  

Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy
Mendell et al.
NEJM 1995;333:832-838.
ABSTRACT | FULL TEXT  

Prednisone in Duchenne Dystrophy: A Randomized, Controlled Trial Defining the Time Course and Dose Response
Griggs et al.
Arch Neurol 1991;48:383-388.
ABSTRACT